| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/25/2001 | WO2001005357A1 Two-component composition for cosmetic or pharmaceutical use |
| 01/25/2001 | WO2001005353A2 USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS |
| 01/25/2001 | WO2001005244A1 Feeds and foods for treating or preventig disease accompanying aging, method for feeding klotho mutant homoanimal and feeds therefor |
| 01/25/2001 | WO2001005230A1 Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof |
| 01/25/2001 | WO2000068399A3 Vector-mediated delivery of integrating transposon sequences |
| 01/25/2001 | WO2000067739A3 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
| 01/25/2001 | WO2000066550A8 New compounds |
| 01/25/2001 | WO2000066111B1 Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions |
| 01/25/2001 | WO2000066093A3 Combined preparations comprising morpholine anthracyclines and anticancer agent |
| 01/25/2001 | WO2000064930A3 Tribonectins |
| 01/25/2001 | WO2000061173A3 Use of pegylated interferon alpha in chronic myeloid leukemia (cml) therapy |
| 01/25/2001 | WO2000061171A3 Uses of mammalian ox2 protein and related reagents |
| 01/25/2001 | WO2000058473A3 Nucleic acids including open reading frames encoding polypeptides; 'orfx' |
| 01/25/2001 | WO2000058472A3 Isolated dna encoding cullin regulators roc1 and roc2, isolated proteins encoded by the same, and methods utilizing the same |
| 01/25/2001 | WO2000058465A3 Flint polypeptide analogs |
| 01/25/2001 | WO2000058293A3 Glucokinase activators |
| 01/25/2001 | WO2000057837A3 Compositions and methods for effecting the levels of cholesterol |
| 01/25/2001 | WO2000056297A3 Pharmaceutical compositions comprising dipeptidy peptidase iv inhibitors for the promotion of growth |
| 01/25/2001 | WO2000056296A3 Compositions for improving fertility |
| 01/25/2001 | WO2000054756A3 Nitrate esters and their use for introducing neuroprotection and cognition enhancement |
| 01/25/2001 | WO2000048447A3 Composition for treatment of external secretion disorders except hypolacrimation |
| 01/25/2001 | WO2000044740A3 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| 01/25/2001 | DE19933164A1 Neue Carbonsäurederivate mit 5,6 substituiertem Pyrimidinring, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten New carboxylic acid derivatives with 5,6-substituted pyrimidine ring, their preparation and use as endothelin receptor antagonists |
| 01/25/2001 | CA2380727A1 Nitrogen containing heterobicycles as factor xa inhibitors |
| 01/25/2001 | CA2380000A1 Odorant receptors |
| 01/25/2001 | CA2379983A1 Dsp-11 dual-specificity map kinase phosphatase |
| 01/25/2001 | CA2379968A1 Gtp-binding protein associated factors |
| 01/25/2001 | CA2379891A1 Quaternary bis-ammonium salt precursors and their uses as prodrugs having an antiparasitic activity |
| 01/25/2001 | CA2379852A1 Method for down-regulating gdf-8 activity |
| 01/25/2001 | CA2379683A1 Identification of pluripotent pre-mesenchymal, pre-hematopoietic progenitor cell |
| 01/25/2001 | CA2379657A1 Phosphate transport inhibitors |
| 01/25/2001 | CA2379627A1 Inhibitor proteins |
| 01/25/2001 | CA2379554A1 Benzimidazolone derivatives and their use as phosphodiesterase inhibitors |
| 01/25/2001 | CA2379545A1 Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists |
| 01/25/2001 | CA2379489A1 Procyanidin oligomers inhibiting matrix metalloproteinases and medicine having effective composition of the same |
| 01/25/2001 | CA2379336A1 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 01/25/2001 | CA2379323A1 Small peptides and methods for downregulation of ige |
| 01/25/2001 | CA2379316A1 Novel aminobenzophenones |
| 01/25/2001 | CA2379286A1 Aminobenzophenones as inhibitors of il-1.beta. and tnf-.alpha. |
| 01/25/2001 | CA2379273A1 Aminobenzophenones as inhibitors of il-1.beta. and tnf-.alpha. |
| 01/25/2001 | CA2379208A1 Spla2 inhibitors |
| 01/25/2001 | CA2379064A1 Bradykinin b1 receptor antagonists |
| 01/25/2001 | CA2379022A1 Cyclic peptide derivatives as inhibitors of integrin .alpha.v.beta.6 |
| 01/25/2001 | CA2378930A1 Electron transfer proteins |
| 01/25/2001 | CA2378917A1 Melanin-concentrating hormone receptor |
| 01/25/2001 | CA2378829A1 Sustained release drug dispersion delivery device |
| 01/25/2001 | CA2378381A1 Method for treating chronic pain using mek inhibitors |
| 01/25/2001 | CA2378249A1 Use of fviia or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis |
| 01/25/2001 | CA2378202A1 New compounds |
| 01/25/2001 | CA2378181A1 Conjugates of sodium channel blockers and methods of using the same |
| 01/25/2001 | CA2378084A1 Novel diphenyl-piperidine derivate |
| 01/25/2001 | CA2378047A1 Heterocyclic compounds for the treatment of migraine |
| 01/25/2001 | CA2378026A1 Novel glycosyl sulfotransferases gst-4.alpha., gst-4.beta., and gst-6 |
| 01/25/2001 | CA2377906A1 Methods for producing and preparing cells for cell therapy |
| 01/25/2001 | CA2377247A1 Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor |
| 01/25/2001 | CA2377092A1 Method for treating chronic pain using mek inhibitors |
| 01/25/2001 | CA2376641A1 Chimeric polypeptides of serum albumin and uses related thereto |
| 01/25/2001 | CA2375954A1 Alpha-hydroxy-gamma-¬¬(carbocyclic-or heterocyclic-substituted)amino|carbonyl|alkanamide derivatives and uses thereof |
| 01/25/2001 | CA2375458A1 Compositions and methods for the treatment of immune related diseases |
| 01/25/2001 | CA2374052A1 Method for treating chronic pain using mek inhibitors |
| 01/25/2001 | CA2340721A1 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |
| 01/24/2001 | EP1070727A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction |
| 01/24/2001 | EP1070708A1 Triazole and imidazole derivatives |
| 01/24/2001 | EP1070707A1 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 01/24/2001 | EP1070140A1 Compositions and methods for treating cells having double minute dna |
| 01/24/2001 | EP1070125A2 Human nucleic acid sequences from normal breast tissue |
| 01/24/2001 | EP1070085A1 DUAL A v?b 3? AND METASTASIS-ASSOCIATED RECEPTOR LIGANDS |
| 01/24/2001 | EP1070084A1 PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase) |
| 01/24/2001 | EP1070083A1 Crystalline forms of 1s- 1alpha (2s*,3r*), 9alpha]-6, 10-dioxo-n- (2-ethoxy-5 -oxo-tetrahydro-3 -furanyl) -9- (1-isoquinolyl) carbonyl]-amino] octahydro-6h -piridazino 1, 2-a] 1,2] diazepin- 1-carboxamide |
| 01/24/2001 | EP1070069A1 Bicyclic hydroxamic acid derivatives |
| 01/24/2001 | EP1070068A1 Granulatimide derivatives for use in cancer treatment |
| 01/24/2001 | EP1070065A1 Azabicyclic 5ht1 receptor ligands |
| 01/24/2001 | EP1070064A1 Antagonists of gonadotropin releasing hormone |
| 01/24/2001 | EP1070060A1 Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists |
| 01/24/2001 | EP1070059A1 Chromanone and thiochromanone derivatives |
| 01/24/2001 | EP1070058A1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides |
| 01/24/2001 | EP1070056A1 Phthalazinone pde iii/iv inhibitors |
| 01/24/2001 | EP1070049A1 Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors |
| 01/24/2001 | EP1070048A1 Calcilytic compounds |
| 01/24/2001 | EP1070047A2 Lipids |
| 01/24/2001 | EP1070046A1 Propanolamine derivatives |
| 01/24/2001 | EP1069915A2 Hydroxylation activated drug release |
| 01/24/2001 | EP1069902A1 Use of phospholipids for the manufacture of a medicament for the prevention of adhesions |
| 01/24/2001 | EP1069897A1 Methods for inhibiting mrp1 |
| 01/24/2001 | EP1069893A2 Use of dexmedetomidine for icu sedation |
| 01/24/2001 | EP1069821A1 Method of controlling proliferation and differentiation of stem and progenitor cells |
| 01/24/2001 | EP0712389B1 Therapeutic compound - fatty acid conjugates |
| 01/24/2001 | EP0694039B1 1,5-benzodiazepine derivatives having cck antagonistic and or agonistic activity |
| 01/24/2001 | EP0573568B1 Use of nicotinic analogs for treatment of degenerative diseases of the nervous system |
| 01/24/2001 | EP0557498B1 Bone-growth-stimulating composition |
| 01/24/2001 | CN1281468A Treatment with anti-ErbB2 antibodies |
| 01/24/2001 | CN1281458A Purine compounds having PDE IV inhibitory activity and methods of synthesis |
| 01/24/2001 | CN1281455A 8-Azabicyclo [3,2,1] octane-3-methanamine derivatives as ligands of D2 and D3 dopamine and 5HT1A and 5HT2 serotonin receptors |
| 01/24/2001 | CN1281451A Benzamine derivatives |
| 01/24/2001 | CN1281447A (i(E))-3-[1-i(n)-butyl-5-[2-(-carboxyphenyl) methoxy-4-chlorophenyl]-1i(H)-pyrazol-4-yl]-2-[(5-methoxy-2,3-dihydrobenzofuran-6-yl) methyl]-prop-2-enoic acid monoargininyl salt |
| 01/24/2001 | CN1281434A Urethanes derived from azacycloalkanes, thio and dithio analogues, production and use thereof as 2,3 epoxysqualene lanesterol cyclase inhibitors |
| 01/24/2001 | CN1281433A Hydroxamic acid derivatives as matrix metalloprotease (MMP) inhibitors |
| 01/24/2001 | CN1281367A Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| 01/24/2001 | CN1281365A Composition and method for increasing insulin activity |
| 01/24/2001 | CN1281357A Medicaments |